OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer

Q4 Medicine

Forum of Clinical Oncology Pub Date : 2015-09-01 DOI:10.1515/fco-2015-0014

N. Soupos, K. Laschos, E. Bournakis, E. Kostouros, G. Aravantinos

引用次数: 0

Abstract

Abstract Olaparib is a potent oral inhibitor of PARP 1 & 2 with biological activity in various solid tumours for patients with germline and/or sporadic BRCA mutations. The aim of this review is to present the results of the various studies which show Olaparib’s efficacy in ovarian cancer

查看原文本刊更多论文

OLAPARIB:一种治疗卵巢癌的PARP抑制剂

奥拉帕尼是一种有效的口服parp1和parp2抑制剂，对多种实体肿瘤患者的种系和/或散发性BRCA突变具有生物活性。这篇综述的目的是介绍各种研究的结果，这些研究表明奥拉帕尼对卵巢癌的疗效

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊